Sysmex (OTCMKTS:SSMXY) Reaches New 1-Year Low – Here’s Why

Sysmex Corporation ADR (OTCMKTS:SSMXY)’s stock price hit a new 52-week low during trading on Tuesday . The company traded as low as $9.66 and last traded at $9.75, with a volume of 291968 shares traded. The stock had previously closed at $10.09.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on SSMXY shares. The Goldman Sachs Group raised shares of Sysmex from a “hold” rating to a “buy” rating in a research report on Thursday, October 9th. Zacks Research raised Sysmex from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 14th. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, Sysmex currently has a consensus rating of “Moderate Buy”.

Sysmex Trading Down 3.4%

The company has a debt-to-equity ratio of 0.12, a current ratio of 3.37 and a quick ratio of 2.49. The business’s 50-day moving average is $11.84 and its two-hundred day moving average is $14.57. The firm has a market cap of $6.14 billion, a P/E ratio of 19.50 and a beta of 1.16.

Sysmex (OTCMKTS:SSMXY) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.16 EPS for the quarter, hitting analysts’ consensus estimates of $0.16. The company had revenue of $826.60 million during the quarter, compared to the consensus estimate of $880.80 million. Sysmex had a net margin of 9.35% and a return on equity of 10.20%. As a group, analysts predict that Sysmex Corporation ADR will post 0.57 earnings per share for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.